| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 514048000 | Phosphorus containing | 72 |
| 20080293667 | Lipid analogs for combating tumors - The invention relates to methods of treating viral infections, and in particular hepatitis B virus. The method comprises administering to a subject in need of such treatment an infection-controlling amount of a phospholipid or phospholipid derivative to inhibit the activity of the viral infection. | 11-27-2008 |
| 20090012037 | Antiviral Compounds - The invention is related to phosphorus substituted anti-viral inhibitory compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds. | 01-08-2009 |
| 20090012038 | Methods for microbial biofilm destruction and interference with microbial cellular physiology - The formation and maintenance of microbial biofilms is shown to be dependent on signaling pathways mediated by cyclic di-GMP. In the absence of such signaling, microbes detach from a biofilm, and thereby become more readily treatable with conventional antibiotics. Chemical or biological means that interfere with cyclic-di-GMP signaling induce biofilm dissolution, providing for a new class of antibiotics. In one embodiment of the invention, the biofilm inhibitor is an analog of cyclic-di-GMP, which competitively or non-competitively blocks signaling. In another embodiment of the invention, the biofilm inhibitor is a genetic sequence that interferes with cyclic-di-GMP synthesis or signaling. | 01-08-2009 |
| 20090023678 | Amino Acid Vitamin Ester Compositions for Controlled Delivery of Pharmaceutically Active Compounds - The invention relates to pharmaceutical compositions that provide sustained-release of a pharmaceutically active compound and to methods of treating or preventing a condition in an animal by administering the pharmaceutical compositions to the animal. When the pharmaceutical compositions are administered to an animal by injection, they form a drug depot that releases the pharmaceutically active compound over time. The pharmaceutical compositions can also be administered orally. | 01-22-2009 |
| 20090143328 | Method of Treating Cancer by Administration of Topical Active Corticosteroids - The present invention provides for methods of treating cancer comprising administering a topical active corticosteroid in conjunction with a form of non-myeloablative conditioning, wherein the above regimen results in a reduction or elimination of cancer cells in an individual. | 06-04-2009 |
| 20090215716 | NITROGUANOSINE-3' 5'-CYCLIC MONOPHOSPHATE COMPOUND AND PROTEIN KINASE G ACTIVATING AGENT - An object of the present invention is to provide a novel compound that is an agonist of guanosine-3′,5′-cyclic monophosphate and has an effect of activating protein kinase G. The present invention provides 8-guanosine-3′,5′-cyclic monophosphate compound which is represented by the following formula, and a pharmaceutical composition, especially a protein kinase G activating agent, which contains the 8-guanosine-3′,5′-cyclic monophosphate compound as an active ingredient. | 08-27-2009 |
| 20090258837 | Analogous compounds of 6-thioguanosine triphosphate, their use in medical fields and processes for their preparation - The invention relates to analogous compounds of 6-thioguanosine triphosphate of general formula (I). A compound of the general formula (I); wherein the dashed bond in the sugar moiety can be either single or double and wherein R1, R2, R3, R4 or R5, equal or different between each other, have general formula -(Int) | 10-15-2009 |
| 20090306007 | NUCLEOSIDES WITH ANTIVIRAL AND ANTICANCER ACTIVITY - The invention provides a compound of formula (I), wherein R | 12-10-2009 |
| 20100016251 | NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS - Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure: | 01-21-2010 |
| 20100016252 | Mannich Base N-Oxide Drugs - Disclosed are Mannich base N-oxides of drugs containing acidic N—H groups. Pharmaceutical compositions comprising a therapeutically effective amount of Mannich base N-oxides, or a N-oxide rearrangement product, pharmaceutically acceptable salt or prodrug thereof, are also disclosed. Further, disclosed are methods of using the compounds, alone or in combination with one or more other active agents or treatments. | 01-21-2010 |
| 20100022467 | ANTI-CANCER PHOSPHONATE ANALOGS - The invention is related to phosphorus substituted anti-cancer compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds. | 01-28-2010 |
| 20100062995 | Transition state structure of human 5'methylthioadenosine phosphorylase - Provided are methods of designing a putative inhibitor of a human 5′-methylthioadenosine phosphorylase (MTAP). Also provided are methods of inhibiting a human MTAP. | 03-11-2010 |
| 20100081628 | NUCLEOSIDE CYCLICPHOSPHATES - Cyclic phosphate of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomers, salts (acid or basic addition salts), hydrates, solvates, or crystalline forms thereof, represented by the following structure: | 04-01-2010 |
| 20100093656 | PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL AGENTS - This invention relates to novel phosphate-modified nucleosides, and methods for producing them, being useful for the prevention or treatment of a viral infection in a mammal, and for preparing oligonucleotides by DNA/RNA polymerase-dependent amplification, e.g. PCR. | 04-15-2010 |
| 20100099643 | Fused Pentacyclic Polyethers - Disclosed are polycyclic polyether compounds of formula I and pharmaceutical compositions comprising such compounds. | 04-22-2010 |
| 20100267656 | MYELOID DIFFERENTIATION INDUCING AGENTS - Myeloid differentiating agents can be used in the treatment of myeloid disorders. | 10-21-2010 |
| 20100279973 | SYNTHESIS OF PURINE NUCLEOSIDES - A process for preparing phosphoramidate prodrugs or cyclic phosphate prodrugs of nucleoside derivatives, which is a compound, its stereoisomers, salts (acid or basic addition salts), hydrates, solvates, or crystalline forms thereof. | 11-04-2010 |
| 20100298255 | Methods for providing personalized medicine test ex vivo for hematological neoplasms - Described herein are methods, devices, and compositions for providing personalized medicine tests for hematological neoplasms. In some embodiments, the methods comprise measuring the efficacy of inducing apoptosis selectively in malignant cells using any number of potential alternative combination drug treatments. In some embodiments, the ex vivo testing is measured using a recently extracted patient hematological samples. In other embodiments, the efficacy is measured ex vivo using an automated flow cytometry platform. For example, by using an automated flow cytometry platform, the evaluation of hundreds, or even thousands of drugs and compositions, can be made ex vivo. Thus, alternative polytherapy treatments can be explored. Non-cytotoxic drugs surprisingly induce apoptosis selectively in malignant cells ex vivo. In some embodiments, the methods described herein comprise evaluating non-cytotoxic drugs. | 11-25-2010 |
| 20100323980 | Improvements to analogous compounds of 6-thioguanosine triphosphate, their use in medical fields and processes for their preparation - The invention relates to analogous compounds of 6-thioguanosine triphosphate of general formula (I). A compound of the general formula (I); wherein the dashed bond in the sugar moiety can be either single or double and wherein R1, R2, R3, R4 or R5, equal or different between each other, have general formula -(Int) | 12-23-2010 |
| 20110015146 | NUCLEOSIDE PHOSPHORAMIDATES - A nucleoside compound having activity against hepatitis C virus is disclosed. | 01-20-2011 |
| 20110086813 | COMPOUNDS FOR TREATING BACTERIAL INFECTIONS - The present invention relates to a novel class of guanine nucleotide analogs which inhibit RelA and Relseq synthetic activity and which possess anti-bacterial activity. The present invention also relates to pharmaceutical compositions that include such compounds, and to methods of use of such compounds or compositions for combating bacteria and treating bacterial infections. | 04-14-2011 |
| 20110112046 | PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL AGENTS - This invention relates to novel phosphate-modified nucleosides, and methods for producing them, being useful for the prevention or treatment of a viral infection in a mammal, and for preparing oligonucleotides by DNA/RNA polymerase-dependent amplification, e.g. PCR. | 05-12-2011 |
| 20110257121 | PURINE NUCLEOSIDE PHOSPHORAMIDATE - Disclosed herein is a compound represented by formula 1 or its hydrate thereof in crystalline or crystal-like form. | 10-20-2011 |
| 20110257122 | NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS - Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure: | 10-20-2011 |
| 20110301112 | FUSED RING THROMBIN RECEPTOR ANTAGONISTS - Fused-ring, heterocyclic-substituted tricyclics of the formula | 12-08-2011 |
| 20120022014 | TETRAHYDROPYRAN NUCLEIC ACID ANALOGS - The present disclosure describes tetrahydropyran nucleoside analogs, oligomeric compounds prepared therefrom and methods of using the oligomeric compounds. More particularly, novel tetrahydropyran nucleoside analogs are provided having at least one chiral substituent that are expected to be useful for enhancing one or more properties of oligomeric compounds such as nuclease resistance and/or binding affinity. In certain embodiments, the oligomeric compounds are expected to hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA. | 01-26-2012 |
| 20120040924 | PURINE NUCLEOSIDE MONOPHOSPHATE PRODRUGS FOR TREATMENT OF CANCER AND VIRAL INFECTIONS - The present invention is directed to compounds, compositions and methods for treating or preventing cancer and viral infections, in particular, HIV, HCV, Norovirus, Saporovirus, HSV-1, HSV-2, Dengue virus, Yellow fever, and HBV in human patients or other animal hosts. The compounds are certain 6-substituted purine monophosphates, and pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof. In particular, the compounds show potent antiviral activity against HIV-1, HIV-2, HCV, Norovirus, Saporovirus, HSV-1, HSV-2, Dengue virus, Yellow fever, and HBV. | 02-16-2012 |
| 20120071434 | SUBSTITUTED NUCLEOTIDE ANALOGS - Disclosed herein are phosphorothioate nucleotide analogs, methods of synthesizing phosphorothioate nucleotide analogs and methods of treating diseases and/or conditions such as viral infections, cancer, and/or parasitic diseases with the phosphorothioate nucleotide analogs. | 03-22-2012 |
| 20120094948 | Analogous Compounds of 6-Thioguanosine Triphosphate, their use in Medical Fields and Processes for their Preparation - The invention relates to analogous compounds of 6-thioguanosine triphosphate of general formula (I). A compound of the general formula (I); wherein the dashed bond in the sugar moiety can be either single or double and wherein R1, R2, R3, R4 or R5, equal or different between each other, have general formula -(Int) | 04-19-2012 |
| 20120115805 | USE OF AT LEAST ONE NUCLEIC ACID TO INFLUENCE THE NATURAL PIGMENTATION PROCESS - A method for influencing the natural pigmentation process of skin or appendages thereof, includes the step of topically contacting the skin or appendages thereof with at least one nucleic acid containing at least 55% guanine nucleotide. | 05-10-2012 |
| 20120135951 | 3'-AZIDO PURINE NUCLEOTIDE PRODRUGS FOR TREATMENT OF VIRAL INFECTIONS - The present invention is directed to compounds, compositions and methods for treating or preventing viral infections, in particular, HIV, and HBV, in human patients or other animal hosts. The compounds are 3′-azido-2′,3′-dideoxy purine monophosphates, and pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof. In particular, the compounds show potent antiviral activity against HIV-1 and HBV. | 05-31-2012 |
| 20120142626 | COMPOUNDS - Disclosed herein are 2′-spiro-nucleosides and derivatives thereof useful for treating a subject infected by hepatitis C virus or dengue virus. | 06-07-2012 |
| 20120172325 | Methods and Compositions for the Treatment of Gastrointestinal Disorders - The present invention features compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, Inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis employing. The methods and compositions employ guanosine 3′,5′-cyclic monophosphate pharmaceutically acceptable salt thereof. | 07-05-2012 |
| 20120178710 | SYNTHESIS OF CYCLIC DIGUANOSINE MONOPHOSPHATE AND THIOPHOSPHATE ANALOGS THEREOF - The invention provides methods for the synthesis of cyclic dinucleotides and thiophosphate analogs thereof as well as a new family of analogs of cyclic diguanosine monophosphate that includes a series of seven phosphorothioate derivatives that includes diastereomers of mono-, di-, and trithiophosphates. | 07-12-2012 |
| 20120196826 | METHODS FOR TRANSDIFFERENTIATION OF BODY TISSUES - The invention relates to methods for transdifferentiation of body tissues which can be used to generate specific cell types needed for regenerating organs or body parts, following cellular degeneration, injury or amputation. The present invention also describes the use of tissue transdifferentiation for treating cancer and autoimmune disease. | 08-02-2012 |
| 20120252752 | Compositions, methods and kits for repressing virulence in gram positive bacteria - Bacterial virulence is repressed by compositions and methods for activating permanently a repressor of virulence factors. Compositions provided contain at least one non-metabolizable analog of guanine, guanosine, isoleucine and valine. | 10-04-2012 |
| 20120258928 | NUCLEOSIDE CYCLICPHOSPHATES - Cyclic phosphate of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomers, salts (acid or basic addition salts), hydrates, solvates, or crystalline forms thereof, represented by the following structure: | 10-11-2012 |
| 20120264709 | NUCLEOTIDE AND OLIGONUCLEOTIDE PRODRUGS - The present invention discloses compounds of formula (I): | 10-18-2012 |
| 20130090302 | ANTIVIRAL COMPOUNDS - The invention is related to phosphorus substituted anti-viral inhibitory compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds. | 04-11-2013 |
| 20130102558 | Methods for Treating HCV - The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), and an inhibitor of cytochrome P450 (e.g., ritonavir). | 04-25-2013 |
| 20130131007 | VITAMIN B12 COMPOSITIONS - This disclosure provides compositions of vitamin B | 05-23-2013 |
| 20130165400 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF - Disclosed herein are nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an infection from a paramyxovirus and/or an orthomyxovirus, with a nucleoside, a nucleotide and an analog thereof. | 06-27-2013 |
| 20130172286 | Functional Food Supplement Intended, In Particular, For Nutrition And For Prevention And Improvement of Neurological Alterations, Neurodegenerative Alterations Or Cognitive Disorders - This invention relates to a functional food supplement, specifically intended to supplement the enteral or oral nutrition of patients with neurological or neurodegenerative alterations, and for the prevention of cognitive or behaviour disorders, especially in the case of elderly persons, where the functional ingredient especially conceived for the nourishment of patients suffering from, or prone to neurological or neurodegenerative alterations, cognitive deterioration or behaviour disorders comprises a mixture of UMP (uridine monophosphate or uridine) and/or IMP (inosine monophosphate or inosine), vitamins of the B group (B1, B6, B9 and B7), phospholipids and gangliosides and sialic acid, as well as a large amount of DHA. | 07-04-2013 |
| 20130172287 | AGENT FOR TREATMENT OF DRY EYE CHARACTERIZED BY COMBINING P2Y2 RECEPTOR AGONIST AND HYALURONIC ACID OR SALT THEREOF, METHOD FOR TREATING DRY EYE, AND USE OF THE P2Y2 RECEPTOR AGONIST AND HYALURONIC ACID OR SALT THEREOF - An agent for treatment of dry eye comprising a combination of a P2Y | 07-04-2013 |
| 20130190265 | Methods of Treating, Reducing the Incidence of, and/or Preventing Ischemic Events - Methods of treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing percutaneous coronary intervention (PCI), comprising administering to the patient a pharmaceutical composition comprising cangrelor. The method may further comprise administering an additional therapeutic agent to the patient, the additional therapeutic agent comprising a P2Y | 07-25-2013 |
| 20130203694 | COMPOUNDS FOR TREATING BACTERIAL INFECTIONS - Rel proteins as a novel therapeutic agent for treating bacterial threats. More specifically, a novel class of compounds of Formula (I) as disclosed herein which possess anti-bacterial activity and which inhibit RelA, RelSeq or RelSpo synthetic activity or bacterial spore formation. Also, pharmaceutical compositions of such compounds and a method of combating bacteria, or treating bacterial infections, by administering to a subject in need thereof such compounds or pharmaceutical compositions. | 08-08-2013 |
| 20130225519 | NUCLEOSIDE PHOSPHORAMIDATES - A nucleoside compound having activity against hepatitis C virus is disclosed. | 08-29-2013 |
| 20130237493 | COMBINATION THERAPY OF 4-(CYCLOPROPYLAMINO)-2-(4-(4-(ETHYLSULFONYL)PIPERAZIN-1-YL)PHENYLAMINO)PY- RIMIDINE-5-CARBOXAMIDE AND FLUDARABINE - The present invention is directed to pharmaceutical compositions and methods of using combination therapies containing 4-(cyclopropylamino)-2-(4-(4-(ethylsulfonyl)piperazin-1-yl)phenylamino)pyrimidine-5-carboxamide, or a pharmaceutically acceptable salt thereof, and fludarabine for the treatment of cell proliferative disorders, such as undesired acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), including diffuse large B cell lymphoma (DLBCL); mantle cell lymphoma, acute lymphocytic leukemia (ALL), follicular lymphoma, Burkitt's lymphoma, small Lymphocytic Lymphoma (SLL) and multiple myeloma. | 09-12-2013 |
| 20130244966 | FATTY ACID ANTIVIRAL CONJUGATES AND THEIR USES - The invention relates to fatty acid antiviral conjugates; compositions comprising an effective amount of a fatty acid antiviral conjugate; and methods for treating or preventing a viral infection comprising the administration of an effective amount of a fatty acid antiviral conjugate. | 09-19-2013 |
| 20130252917 | COMBINATION THERAPY OF 4-(3-(2H-1,2,3-TRIAZO-2-YL)PHENYLAMINO)-2-((1R,2S)-2-AMINOCYCLOHEXYLAMINO- )PYRIMIDINE-5-CARBOXAMIDE AND FLUDARABINE - The present invention is directed to pharmaceutical compositions and methods of using combination therapies containing 4-(3-(2H-1,2,3-triazol-2-yl)phenylamino)-2-(1R,2S)-2-aminocyclohexylamino)pyrimidine-5-carboxamide, or a pharmaceutically acceptable salt thereof, and fludarabine for the treatment of cell proliferative disorders, such as undesired acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), including diffuse large B cell lymphoma (DLBCL); mantle cell lymphoma, acute lymphocytic leukemia (ALL), follicular lymphoma, Burkitt's lymphoma, small Lymphocytic Lymphoma (SLL) and multiple myeloma. | 09-26-2013 |
| 20130303478 | Maintenance of Platelet Inhibition During Antiplatelet Therapy - A method for reducing or maintaining platelet inhibition in a patient by administering cangrelor prior to an invasive procedure is described. The method of this invention can be used for patients in need of antiplatelet therapy or at risk of thrombosis. The method can further be used in patients who were previously treated with long-acting platelet inhibitors without increasing the risk of excessive bleeding. | 11-14-2013 |
| 20130316969 | ANTIVIRAL PHOSPHONATE ANALOGS - The invention is related to phosphorus substituted compounds with antiviral activity, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds. | 11-28-2013 |
| 20130316970 | NUCLEOTIDE ANALOGUE, METHOD OF SYNTHESIS OF NUCLEOTIDE ANALOGUE, USE OF NUCLEOTIDE ANALOGUE, ANTIVIRAL PRO-NUCLEOTIDE, PHARMACEUTICAL COMPOSITION - The object of the invention are nucleotide analogues, antiviral pro-nucleotides, a use of nucleotide analogues and pharmaceutical composition, a phosphorylating agent for synthesis of nucleotide analogue, and a method of synthesis of nucleotide analogue. More precisely, the invention applies to the new group of nucleotide analogues and their use in partial or complete inhibition of human immunodeficiency virus (HIV). | 11-28-2013 |
| 20130338095 | Chemosensory Receptor Ligand-Based Therapies - Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administering a composition comprising a chemosensory receptor ligand. Also provided herein are chemosensory receptor ligand compositions and methods for the preparation thereof for use in the methods of the present invention. | 12-19-2013 |
| 20140038916 | O-(SUBSTITUTED BENZYL) PHOSPHORAMIDATE COMPOUNDS AND THERAPEUTIC USE - This application discloses novel phosphoramidate and phosphonoamidate prodrugs of nucleosides, nucleotides, C-nucleosides, C-nucleotides, phosphonates, and other alcohol-containing drugs; use of these prodrugs for treatment of infectious diseases and cancers, in particular, liver infections and cancers; and methods of preparing these novel phosphoramidate and phosphonoamidate prodrugs. | 02-06-2014 |
| 20140066395 | PURINE NUCLEOSIDE MONOPHOSPHATE PRODRUGS FOR TREATMENT OF CANCER AND VIRAL INFECTIONS - The present invention is directed to compounds, compositions and methods for treating or preventing cancer and viral infections, in particular, HIV, HCV, Norovirus, Saporovirus, HSV-1, HSV-2, Dengue virus, Yellow fever, and HBV in human patients or other animal hosts. The compounds are certain 6-substituted purine monophosphates, and pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof. In particular, the compounds show potent antiviral activity against HIV-1, HIV-2, HCV, Norovirus, Saporovirus, HSV-1, HSV-2, Dengue virus, Yellow fever, and HBV. | 03-06-2014 |
| 20140088034 | NITRIC OXIDE/cGMP PATHWAY INHIBITION OF VLA-4 RELATED CELL ADHESION - The invention provides methods of treating nitric oxide/cGMP pathway-cell adhesion disorders and related pharmaceutical compositions, diagnostics, screening techniques and kits. In one embodiment, the invention relates to a method for down-regulating α | 03-27-2014 |
| 20140094425 | METHODS FOR TRANSDIFFERENTIATION OF BODY TISSUES - The invention relates to methods for transdifferentiation of body tissues which can be used to generate specific cell types needed for regenerating organs or body parts, following cellular degeneration, injury or amputation. The present invention also describes the use of tissue transdifferentiation for treating cancer and autoimmune diseases. | 04-03-2014 |
| 20140206640 | 2'-AZIDO SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES - The present invention relates to 2′-Azido Substituted Nucleoside Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein B, X, R | 07-24-2014 |
| 20140221304 | 5'-SUBSTITUTED NUCLEOSIDE ANALOGS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES - The present invention relates to 5′-Substituted Nucleoside Analogs of Formula (I): and pharmaceutically acceptable salts thereof, wherein B, X, Z, R | 08-07-2014 |
| 20140303107 | DRUG FORMULATIONS - The invention provides derivatives of decitabine with superior chemical stability and shelf life, with similar physiological activity. The derivatives are provided in a non-aqueous formulation, which further stabilizes the derivatives. Methods of treating one or more myelodysplastic syndromes, leukemia, or solid tumours using the formulations are described. | 10-09-2014 |
| 20140303108 | CYCLIC NUCLEOTIDE ANALOGS - Disclosed herein are cyclic nucleotide analogs, methods of synthesizing cyclic nucleotide analogs and methods of treating diseases and/or conditions such as viral infections, cancer, and/or parasitic diseases with cyclic nucleotide analogs. | 10-09-2014 |
| 20140315850 | 2',3'-Dideoxy-2'-alpha-Fluoro-2'-beta-C-Methylnucleosides and Prodrugs Thereof - The present invention is made to fulfill the foregoing need. Since most of antiHN nucleosides are 2′,3′-dideoxynucleosides that have been proved to be excellent substrates of kinases for the phosphorylations. 2′,3′-Dideoxy-2,-a-fluoro-2′-{3-C-methyl-nucleosides can be considered as one unique class of 2′,3′-dideoxynucleosides to be good substrate of kinases because fluorine mimics hydrogen. It also can be considered as ribo-nucleosides to incorporate into RNA of HCV because 2′-fluorine-a mimics 2′-a-OH group. | 10-23-2014 |
| 20150051167 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF - Disclosed herein are nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an infection from a paramyxovirus and/or an orthomyxovirus, with a nucleoside, a nucleotide and an analog thereof. | 02-19-2015 |
| 20150141363 | SUBSTITUTED NUCLEOTIDE ANALOGS - Disclosed herein are phosphorothioate nucleotide analogs, methods of synthesizing phosphorothioate nucleotide analogs and methods of treating diseases and/or conditions such as viral infections, cancer, and/or parasitic diseases with the phosphorothioate nucleotide analogs. | 05-21-2015 |
| 20150291650 | Process for Preparing Nucleoside Prodrugs - Provided is a process for preparing phosphoramidates of nucleosides where a desired enantiomer, having regard to the asymmetric chiral center of the phosphorus atom P, is provided in an enriched amount. The process comprises admixing a nucleoside with a phosphorochloridate in the presence of a catalyst comprising a metal salt selected from the group consisting of salts of Cu, Fe, La and Yb. | 10-15-2015 |
| 20150366887 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF - Disclosed herein are nucleosides, nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a Filoviridae virus infection with one or more nucleosides and/or nucleotide analogs. | 12-24-2015 |
| 20160002281 | D-AMINO ACID COMPOUNDS FOR LIVER DISEASE - Provided herein are compounds, compositions and methods for the treatment of liver disease and conditions, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. | 01-07-2016 |
| 20160024136 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF - Disclosed herein are nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a HCV infection with one or more nucleotide analogs. | 01-28-2016 |
| 20160115186 | PHOSPHORIC ACID/PHOSPHONIC ACID DERIVATIVES AND MEDICINAL USES THEREOF - The present invention relates to phosphoric acid/phosphonic acid derivatives shown by formula (I), wherein, R | 04-28-2016 |
| 20160130296 | Oligonucleotide Analogues Incorporating 5-Aza-Cytosine Therein - Oligonucleotide analogues are provided that incorporate 5-aza-cytosine in the oligonucleotide sequence, e.g., in the form of 5-aza-2′-deoxycytidine (decitabine) or 5-aza-cytidine. In particular, oligonucleotide analogues rich in decitabine-deoxyguanosine islets (DpG and GpD) are provided to target the CpG islets in the human genome, especially in the promoter regions of genes susceptible to aberrant hypermethylation. Such analogues can be used for modulation of DNA methylation, such as effective inhibition of methylation of cytosine at the C-5 position. Methods for synthesizing these oligonucleotide analogues and for modulating nucleic acid methylation are provided. Also provided are phosphoramidite building blocks for synthesizing the oligonucleotide analogues, methods for synthesizing, formulating and administering these compounds or compositions to treat conditions, such as cancer and hematological disorders. | 05-12-2016 |
| 20160176911 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | 06-23-2016 |
